Hoffmann-la Roche

This study tests an experimental drug (RO7268489) added to standard treatment (ocrelizumab) in 360 adults with progressive multiple sclerosis. The goal is to see if it can delay worsening of disability, such as walking speed and hand function. Participants are randomly assigned t…

This study tests the drug ocrelizumab in 60 Chinese adults with relapsing or primary progressive multiple sclerosis (MS). The goal is to see how well it controls disease activity and reduces relapses over 48 weeks. Participants receive the drug by infusion, and researchers track …

This early-stage study tests a new drug called RO7812653 in 50 people with early Alzheimer's. The main goal is to check if the drug is safe and how the body processes it. Participants receive a single dose injected into the spine and are monitored closely for side effects. This r…

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a common cause of vision loss in older adults. About 1,000 people who have already been in earlier studies will take part.…

This early-stage study tests an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The main goal is to check safety and how well the drug is tolerated. About 132 participants will r…

This early-phase study tests two drugs, mosunetuzumab and venetoclax, for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. The goal is to see if these drugs are safe and can shrink or control the cancer. About 137 adults will t…

This study is testing several different treatment combinations for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective these treatments are. About 200 participants will be enrolled, and the study can add new treatments as they become availa…

This study tests an experimental drug called trontinemab in 800 people with early Alzheimer's (mild memory loss to mild dementia). The goal is to see if it can slow down worsening of symptoms over 72 weeks. Participants will receive either the drug or a placebo, and researchers w…

This study is testing several new combinations of immunotherapy drugs in people with advanced liver cancer that cannot be removed by surgery. The goal is to see if these combinations can shrink tumors or slow the disease. About 518 adults who have not had prior systemic treatment…

This study tests a drug called satralizumab in people with two rare autoimmune diseases that cause brain inflammation (NMDAR and LGI1 encephalitis). The goal is to see if the drug can improve disability and reduce the need for emergency treatments. About 152 adults will receive e…

This study is testing a new digital platform designed to help doctors and patients better monitor multiple sclerosis (MS). Researchers want to see if the platform is easy to use and if it improves care. About 500 people with relapsing-remitting MS will use a smartphone app, while…